Thomas Slavin, MD, FACMG, DABCC, Discusses the Use of the myChoice CDx for Ovarian Cancer

Video

New guidelines published by the American Society for Clinical Oncology (ASCO) on the use of PARP inhibitors in the management of ovarian cancer included the myChoice CDx as the sole companion diagnostic to be used in this space.

New guidelines published by the American Society for Clinical Oncology (ASCO) detail recommendations on the use of PARP inhibitors in the management of ovarian cancer.

“The purpose of this guideline is to provide clinicians, other health care practitioners, patients, and caregivers with recommendations regarding the role of [PARP inhibitors] in the management of [epithelial ovarian, tubal, or primary peritoneal cancer; EOC] based on the best available evidence,” the authors of the guidelines wrote.

Notably, the guidelines specifically cite the myChoice CDx as the sole companion diagnostic to be used in this space. Further, the myChoice CDx was recommended for use in both newly diagnosed and recurrent ovarian cancer.

In an interview with CancerNetwork®, Thomas Slavin, MD, FACMG, DABCC, senior vice president of Medical Affairs for Myriad Oncology, the developer of the diagnostic, spoke about the inclusion of the myChoice CDx in the recommendations and what the diagnostic tool offers for this patient population.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer [news release]. Salt Lake City. Published August 21, 2020. Accessed September 11, 2020. https://finance.yahoo.com/news/american-society-clinical-oncology-exclusively-110500791.html

Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content
The FDA decision is based on data from a pooled analysis of phase 1/2 study data from 2 trials evaluating the agent in advanced/metastatic PROC.

JSKN003 Receives FDA Fast Track Designation in Advanced PROC

Roman Fabbricatore
October 28th 2025
Article

The FDA decision is based on data from a pooled analysis of phase 1/2 study data from 2 trials evaluating the agent in advanced/metastatic PROC.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Explore a rare case of vulvar epithelioid sarcoma, highlighting the role of SMARCB1 loss and the challenges of radiotherapy in treatment.

Unraveling the Complexities of Proximal-Type Epithelioid Sarcoma of the Vulva

Fatimah M. Kaabi, MBBS;Chaker Zaidi, MD, PhD;Fatimah Abdullah Alessa, MBBS;Yasser Sorour, MD, PhD
October 27th 2025
Article

Target Folate Receptor Alpha in Ovarian Cancer?

Target Folate Receptor Alpha in Ovarian Cancer?

Dmitriy Zamarin, MD, PhD
September 17th 2018
Podcast

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

In terms of OS among patients with non-tBRCA–mutated, HRD-positive disease, the median value was not reached in either durvalumab arm.

Durvalumab Quadruplet Displays Nonsuperior OS in Advanced Ovarian Cancer

Kyle Doherty
October 19th 2025
Article

In terms of OS among patients with non-tBRCA–mutated, HRD-positive disease, the median value was not reached in either durvalumab arm.

Data from the ROSELLA trial show a consistent benefit with relacorilant plus nab-paclitaxel across PROC subgroups.

Relacorilant Regimen Improves PFS in Platinum-Resistant Ovarian Cancer

Ashling Wahner
October 19th 2025
Article

Data from the ROSELLA trial show a consistent benefit with relacorilant plus nab-paclitaxel across PROC subgroups.